New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs Introduced

Having achieved CE Mark for sales in Europe and the UK, ThinkSono is now collaborating with Clarius on clinical studies in the United States to prepare for FDA submission

AI-Guded Ultrasound System

Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT). ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval.

DVT

DVT is a blood clot found commonly in the leg and is a leading cause of preventable hospital death in Europe and the United States. Patients often wait for hours or days for test results performed by ultrasound-trained clinicians. ThinkSono Guidance enables non-ultrasound trained healthcare professionals to use the Clarius handheld ultrasound scanner to collect DVT exam data for a qualified clinician to review. This can speed up the diagnosis from several hours to as little as 15 minutes.

Fouad-Al Noor, CEO and Co-founder of ThinkSono

“Clarius has been an invaluable partner in helping us bring ThinkSono Guidance to market quickly to help non-ultrasound trained staff such as nurses improve the DVT pathway by scanning for DVTs at the bedside. Our App integrates seamlessly with Clarius scanners through the research SDK, which sends streams of real-time data to the ThinkSono App that in turn providing instant guidance to users as they perform an ultrasound exam. Our partnership with Clarius has been vital in running our clinical studies.”

Further clinical studies are currently underway in the United States at NYU Longone Health and Temple Health, these are based on the successful multi-site clinical trials held in Europe last year, which were used to obtain the Class IIb CE mark for the ThinkSono Guidance System.

ThinkSono purchased their first Clarius scanner in 2017 and were the first partner to use the Clarius Cast API, developed for researchers and AI companies to help bring technologies to market more quickly by leveraging easy access to real-time ultrasound data to train AI algorithms and deploy AI solutions. ThinkSono now uses Clarius’ Solum software development kit (SDK), enabling the company to create a bespoke solution tailored to their DVT application. ThinkSono will be marketing and selling the complete DVT solution including a Clarius ultrasound scanner directly starting in the UK, Germany and Greece.

Kris Dickie, Chief Technology Officer at Clarius

“Working closely with ThinkSono since the inception of their company, when they utilized our first-generation high-performance scanners, has been a delight. Seeing unique AI tools like theirs being developed for commercial use on our platform truly validates the technology beyond the already broad clinical segments that Clarius currently serves.”

Third-party Developers

The Clarius SDK suite empowers third-party developers to seamlessly integrate AI-powered ultrasound software with Clarius handheld ultrasound systems, the Clarius App, and the Clarius Cloud exam management platform. It provides a set of tools enabling developers to quickly take their solution from code directly to the clinician’s hand without creating custom hardware.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.